Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte R with Dextrose 5% is an intravenous solution providing electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) and dextrose. Dextrose provides calories and may prevent ketosis; electrolytes maintain or restore acid-base balance and provide essential ions for cellular function.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Replacement of extracellular fluid and electrolytes in conditions such as dehydration, hypovolemia, and metabolic acidosis,Maintenance fluid therapy in patients who cannot take oral fluids,Perioperative fluid and electrolyte management
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion at a rate of 125-200 m L/hour (3 m L/kg/hour) for fluid and electrolyte maintenance, adjusted based on clinical status, serum electrolytes, and glucose monitoring.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable as a composite solution; glucose half-life ~1.5-2 h in normal individuals, extended in renal impairment; electrolytes follow body homeostasis.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Dextrose is metabolized via glycolysis and subsequent pathways; electrolytes are excreted or reabsorbed as needed; acetate and gluconate are metabolized to bicarbonate in the liver.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal: ~100% as water, electrolytes, and glucose; no biliary or fecal elimination of active drug components.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
None for water and electrolytes; glucose is not protein bound.
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
0.2 L/kg for water; electrolytes distribute according to body compartments (ECF ~0.2 L/kg, ICF ~0.4 L/kg); glucose initial Vd ~0.2 L/kg.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100%.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
No specific dose adjustment for GFR; use with caution in renal impairment due to risk of fluid overload and electrolyte disturbances. Monitor serum potassium, phosphate, and magnesium levels closely. In severe renal impairment (GFR <30 m L/min), consider alternative fluids with lower potassium and phosphate content.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to altered metabolism of dextrose and lactate; monitor glucose and lactate levels. Avoid in patients with lactic acidosis or severe hepatic dysfunction.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Intravenous infusion based on body weight: 5-10 m L/kg per dose for maintenance, repeated as needed; typical rate: 100-150 m L/kg/day for fluid maintenance, adjusted for clinical status. Monitor glucose and electrolytes frequently.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Use with caution due to age-related decline in renal function and higher risk of fluid overload. Start at lower infusion rates (100-125 m L/hour) and titrate based on clinical response and monitoring of electrolytes, renal function, and volume status.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
None.
None
Monitor serum electrolytes, fluid balance, and acid-base status closely,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload,Avoid rapid infusion or large volumes in patients with reduced renal function,Use with caution in patients with diabetes mellitus due to dextrose content
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hypernatremia,Hypersensitivity to any component,Severe metabolic alkalosis,Anuria or oliguria (unless due to hypovolemia)
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No specific food interactions with IV administration. However, oral intake should be coordinated with IV therapy to avoid fluid or electrolyte imbalance. In patients with diabetes, adjust oral carbohydrate intake to account for dextrose calories.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
No known teratogenic risk. Dextrose and electrolytes are physiologic components; no fetal harm reported with standard use. High dextrose concentrations may cause fetal hyperglycemia, particularly in gestational diabetes.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Compatible with breastfeeding. Dextrose and electrolytes are normal milk constituents; no adverse effects expected. M/P ratio not applicable.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No standard dose adjustment required. Increased plasma volume may necessitate higher fluid load; adjust rate based on clinical status, glucose tolerance, and hemodilution.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
Isolyte R w/ Dextrose 5% is an isotonic, balanced electrolyte solution with 5% dextrose, providing 170 kcal/L. It is contraindicated in patients with lactate metabolism disorders (e.g., severe hepatic failure) due to lactate content. Monitor serum glucose closely in diabetic patients; dextrose may cause hyperglycemia. Do not administer simultaneously with blood through same IV line due to risk of hemolysis. Check for particulate matter and container leaks before use.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This intravenous solution provides fluids, sugars, and electrolytes to maintain hydration and nutritional balance.,Tell your healthcare provider if you have diabetes, kidney disease, liver disease, or a history of heart failure.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your provider if you feel swelling in your arms or legs, shortness of breath, or rapid weight gain (signs of fluid overload).,Blood sugar and electrolyte levels will be monitored regularly during treatment.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte R with Dextrose 5% is an intravenous solution providing electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) and dextrose. Dextrose provides calories and may prevent ketosis; electrolytes maintain or restore acid-base balance and provide essential ions for cellular function.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate of 125-200 m L/hour (3 m L/kg/hour) for fluid and electrolyte maintenance, adjusted based on clinical status, serum electrolytes, and glucose monitoring.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No known teratogenic risk. Dextrose and electrolytes are physiologic components; no fetal harm reported with standard use. High dextrose concentrations may cause fetal hyperglycemi. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.